Quarterly results · SUNPHARMA
SUN PHARMACEUTICAL IND L reported revenue of ₹16,199 cr and net profit of ₹1,995 cr in Q2 FY27 (quarter ended 30 Sept 2026). Below is the full quarter-wise results table with revenue, operating profit, margins, tax, EPS and annual history — updated when Yahoo Finance publishes updated financial statements; exchange filings can appear earlier.
Next results date
30 Oct 2026
Board Meeting Intimation for consideration and approval the Unaudited Financial Results for the quarter and half year ended 30 September 2026
| Quarter | Q2 FY27 |
|---|---|
| Quarter ended | 30 Sept 2026 |
| Revenue | ₹16,199 cr |
| Revenue YoY | — |
| Operating profit | ₹3,986 cr |
| Operating margin | 24.6% |
| Net profit | ₹1,995 cr |
| Net profit YoY | — |
| Net profit QoQ | -31.1% |
| Net margin | 12.3% |
| Basic EPS | ₹8.30 |
| TTM revenue | ₹61,411 cr |
| TTM net profit | ₹10,973 cr |
| TTM net margin | 17.9% |
SUN PHARMACEUTICAL IND L (SUNPHARMA) has reported its Q2 FY27 results for the quarter ended 2026-09-30. The company posted revenue of ₹16,199 cr and a net profit of ₹1,995 cr, translating into earnings per share of ₹8.30.
Operating profit for the quarter stood at ₹3,986 cr, an operating margin of 24.6%.
Revenue
₹16,199 cr
— YoY
Net profit
₹1,995 cr
— YoY
Operating profit
₹3,986 cr
— YoY
EPS
₹8.30
— YoY
Swipe sideways to see all columns →
| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|---|---|---|---|---|---|---|---|
| Q2 FY272026-09-30 | ₹16,199 cr | ₹3,986 cr | ₹1,995 cr | 24.6% | 12.3% | ₹8.30 | — | -31.1% |
| Q1 FY272026-06-30 | ₹15,184 cr | ₹3,557 cr | ₹2,895 cr | 23.4% | 19.1% | ₹12.10 | +27.0% | +6.7% |
| Q4 FY262026-03-31 | ₹14,560 cr | ₹2,752 cr | ₹2,714 cr | 18.9% | 18.6% | ₹11.30 | +26.2% | -19.4% |
| Q3 FY262025-12-31 | ₹15,469 cr | ₹4,062 cr | ₹3,369 cr | 26.3% | 21.8% | ₹14.00 | — | +47.8% |
| Q1 FY262025-06-30 | ₹13,786 cr | ₹3,372 cr | ₹2,279 cr | 24.5% | 16.5% | ₹9.50 | — | +6.0% |
| Q4 FY252025-03-31 | ₹12,816 cr | ₹2,761 cr | ₹2,150 cr | 21.5% | 16.8% | ₹9.00 | — | — |
| TTM (last 4 quarters) | ₹61,411 cr | ₹14,357 cr | ₹10,973 cr | 23.4% | 17.9% | ₹45.70 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
| Particulars | Q2 FY272026-09-30 | Q1 FY272026-06-30 | Q4 FY262026-03-31 | Q3 FY262025-12-31 | Q1 FY262025-06-30 | Q4 FY252025-03-31 |
|---|---|---|---|---|---|---|
| Revenue / Sales | ₹16,199 cr | ₹15,184 cr | ₹14,560 cr | ₹15,469 cr | ₹13,786 cr | ₹12,816 cr |
| Total expenses | ₹12,288 cr | ₹11,627 cr | ₹11,808 cr | ₹11,407 cr | ₹10,414 cr | ₹10,055 cr |
| Gross profit | — | ₹12,220 cr | ₹11,759 cr | ₹12,524 cr | ₹10,971 cr | ₹10,178 cr |
| Operating profit (EBIT) | ₹3,986 cr | ₹3,557 cr | ₹2,752 cr | ₹4,062 cr | ₹3,372 cr | ₹2,761 cr |
| Operating margin | 24.6% | 23.4% | 18.9% | 26.3% | 24.5% | 21.5% |
| Interest cost | ₹74.67 cr | ₹99.67 cr | ₹85.89 cr | ₹78.36 cr | ₹74.8 cr | ₹49.14 cr |
| Profit before tax | ₹3,159 cr | ₹4,099 cr | ₹3,551 cr | ₹4,227 cr | ₹3,173 cr | ₹3,254 cr |
| Tax expense | ₹1,158 cr | ₹1,188 cr | ₹828 cr | ₹826 cr | ₹870 cr | ₹1,094 cr |
| Effective tax rate | 36.6% | 29.0% | 23.3% | 19.5% | 27.4% | 33.6% |
| Net profit (PAT) | ₹1,995 cr | ₹2,895 cr | ₹2,714 cr | ₹3,369 cr | ₹2,279 cr | ₹2,150 cr |
| Net profit margin | 12.3% | 19.1% | 18.6% | 21.8% | 16.5% | 16.8% |
| Basic EPS | ₹8.30 | ₹12.10 | ₹11.30 | ₹14.00 | ₹9.50 | ₹9.00 |
| Diluted EPS | — | ₹12.10 | ₹11.30 | ₹14.00 | ₹9.50 | ₹9.00 |
| Growth | Q2 FY27 | Q1 FY27 | Q4 FY26 | Q3 FY26 | Q1 FY26 | Q4 FY25 |
|---|---|---|---|---|---|---|
| Revenue YoY | — | +10.1% | +13.6% | — | — | — |
| Revenue QoQ | +6.7% | +4.3% | -5.9% | +12.2% | +7.6% | — |
| Operating profit YoY | — | +5.5% | -0.3% | — | — | — |
| Operating profit QoQ | +12.0% | +29.3% | -32.3% | +20.5% | +22.1% | — |
| Net profit YoY | — | +27.0% | +26.2% | — | — | — |
| Net profit QoQ | -31.1% | +6.7% | -19.4% | +47.8% | +6.0% | — |
| EPS YoY | — | +27.4% | +25.6% | — | — | — |
| EPS QoQ | -31.4% | +7.1% | -19.3% | +47.4% | +5.6% | — |
Full-year performance for SUN PHARMACEUTICAL IND L, useful for reading each quarter in context.
| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY232023-03-31 |
|---|---|---|---|---|
| Revenue / Sales | ₹58,220 cr | ₹52,041 cr | ₹47,758 cr | ₹43,279 cr |
| Total expenses | ₹44,625 cr | ₹39,460 cr | ₹37,290 cr | ₹34,002 cr |
| Gross profit | ₹45,047 cr | ₹39,844 cr | ₹35,689 cr | ₹31,336 cr |
| Operating profit (EBIT) | ₹13,595 cr | ₹12,581 cr | ₹10,468 cr | ₹9,277 cr |
| Operating margin | 23.4% | 24.2% | 21.9% | 21.4% |
| Interest cost | ₹339 cr | ₹231 cr | ₹238 cr | ₹172 cr |
| Profit before tax | ₹15,119 cr | ₹13,752 cr | ₹11,088 cr | ₹9,408 cr |
| Tax expense | ₹3,554 cr | ₹2,772 cr | ₹1,439 cr | ₹848 cr |
| Effective tax rate | 23.5% | 20.2% | 13.0% | 9.0% |
| Net profit (PAT) | ₹11,479 cr | ₹10,929 cr | ₹9,576 cr | ₹8,474 cr |
| Net profit margin | 19.7% | 21.0% | 20.1% | 19.6% |
| Basic EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 |
| Diluted EPS | ₹47.80 | ₹45.60 | ₹39.90 | ₹35.30 |
Topline for Q2 FY27 came in at ₹16,199 cr, and ₹15,184 cr in the preceding Q1 FY27 quarter.
On a sequential basis revenue grew +6.7%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹12,288 cr, or 75.9% of revenue.
Net profit of ₹1,995 cr works out to a net margin of 12.3%.
Below the operating line, SUN PHARMACEUTICAL IND L reported profit before tax of ₹3,159 cr, a tax charge of ₹1,158 cr (effective rate 36.6%), interest cost of ₹74.67 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹2,895 cr in Q1 FY27 to ₹1,995 cr in Q2 FY27, a change of -31.1%.
Across the trailing four quarters SUN PHARMACEUTICAL IND L has generated revenue of ₹61,411 cr and net profit of ₹10,973 cr, a trailing net margin of 17.9%. The trailing view smooths out one-off quarters and is the number most valuation multiples are built on.
On a full-year basis, FY26 revenue was ₹58,220 cr with net profit of ₹11,479 cr and EPS of ₹47.80, versus the prior year where revenue grew +11.9% and profit grew +5.0%.
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A single weak quarter matters less than the direction over three to four consecutive quarters.
SUN PHARMACEUTICAL IND L has intimated the exchange that its board meets on 30 Oct 2026 to approve financial results. The figures shown here update when Yahoo Finance publishes the corresponding statement data, which can lag the filing.
Financial figures here are supplied through Yahoo Finance fundamentals and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
In Q2 FY27 (quarter ended 30 Sept 2026), SUN PHARMACEUTICAL IND L reported revenue of ₹16,199 cr and net profit of ₹1,995 cr. EPS stood at ₹8.30.
SUN PHARMACEUTICAL IND L posted a net profit margin of 12.3% and an operating margin of 24.6% in Q2 FY27. On a trailing twelve-month basis, revenue is ₹61,411 cr and net profit ₹10,973 cr.
SUN PHARMACEUTICAL IND L net profit changed -31.1% quarter on quarter, from ₹2,895 cr in Q1 FY27 to ₹1,995 cr in Q2 FY27.
The board of SUN PHARMACEUTICAL IND L meets on 30 Oct 2026 to consider and approve the financial results, as per the exchange filing.
Our latest SUNPHARMA results coverage — "Sun Pharmaceutical Industries Limited Q2 FY27 Results: Net Profit ₹1,995 cr" — breaks down revenue, profit, margins and management commentary.
For FY26, SUN PHARMACEUTICAL IND L reported full-year revenue of ₹58,220 cr and net profit of ₹11,479 cr, with EPS of ₹47.80.
Past results dates for SUNPHARMA will be listed here from the exchange calendar.
Results dates: NSE board-meeting calendar. Financial figures: Yahoo Finance fundamentals, not a direct exchange filing feed. Last successful data fetch 31 Oct 2026. Figures can be delayed; results change only when the provider publishes them. For information only, not investment advice.
